Cirrhosis: Forever?;Cirrhose: Toujours?

Gastroenterologie Clinique et Biologique

Volumn 24, Issue 10, 2000, Pages 877-882

  Bioulac Sage, Paulette ^a,b   Blanc, Jean Frédéric ^b,c   Lepreux, Sébastien ^a,b   Balabaud, Charles ^b,c   Rosenbaum, Jean ^b   Desmoulière, Alexis ^b  

^a HÔPITAL PELLEGRIN   (France)

^b INSERM   (France)

^c HÔPITAL SAINT ANDRÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE COURSE; HISTOPATHOLOGY; LIVER CIRCULATION; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER NODULE; LIVER PARENCHYMA; REVIEW;

ANIMALS; HUMANS; LIVER CIRRHOSIS; PROGNOSIS;

EID: 0033763793     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Posthepatitic, postnecrotic, and nutritional cirrhosis. A pathologic analysis
2. Pathologic aspects of cirrhosis
3. The morphology of cirrhosis. Recommendations on definition, nomenclature, and classification by a working group sponsored by the World Health Organization
4. Morphological classification of cirrhosis: A reevaluation
5. Liver cirrhosis
6. Physioanatomic considerations
7. Thrombosis and phlebitis in the pathogenesis of portal hypertension and cirrhosis: The 2-hit hypothesis for the pathogenesis of chronic liver disease
8. Hepatic and portal vein thrombosis in cirrhosis: Possible role in development of paprenchymal extinction and portal hypertension
9. Injection-corrosion studies of normal and cirrhotic livers
10. Functional hepatic flow and Doppler-assessed total hepatic flow in control subjects and in patients with cirrhosis
11. Vascular pattern of the cirrhotic liver
12. Portographic opacification of hepatic veins and (anomalous) anastomoses between the portal and hepatic veins in cirrhosis-indication of extensive intrahepatic shunts
13. Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent
14. Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment
15. Reversal of 'cirrhosis' in idiopathic haemochromatosis following long-term intensive venesection therapy
16. Regression of hepatic fibrosis in hepatitis C with long-term interferon treatment
17. Reversibility of hepatic fibrosis in autoimmune hepatitis
18. Reversal of cirrhosis in hemochromatosis following long-term phlebotomy
19. Reversibility of extensive liver damage in galactosemia
20. Conversion of micronodular cirrhosis into macronodular cirrhosis
21. Cirrhosis and hepatoma in alcoholics
22. The diagnosis of cirrhosis: Clinical relevance and methodology
23. Cholangiocarcinoma tossing in Van Meyenburg complex associated with hepatocellular carcinoma in genetic haemochromatosis
24. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view. The Multivirc Group
25. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy
26. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: A pilot trial of interferon nonresponders
27. Long-term administration of interferon-alpha in non-responder patients with chronic hepatitis C: Follow-up of liver fibrosis over 5 years
28. Changes in serum tissue inhibitor of matrix metalloproteinase-1 after interferon alpha treatment in chronic hepatitis C
29. Cirrhosis of the liver: A reversible disease?
30. Is liver fibrosis reversible?
31. New insights into hepatic stellate cell activation: The simple becomes complex
32. Fibrogensis II. Metalloproteinases and their inhibitors in liver fibrosis
33. Proliferation and phenotypic modulation of portal fibroblasts in the early stages of cholestatic fibroses in the rat
34. Mechanisms of myofibroblast activity and phenotypic modulation
35. A monoclonal antibody against α-smooth muscle actin: A new probe for smooth muscle differentiation
36. α-Smooth muscle actin is transiently expressed by myofibroblasts during experimental wound healing
37. Prolonged bile duct obstruction: A new experimental model for cirrhosis in the rat
38. Quantitative aspects of the parenchyma-stroma relationship in experimentally induced cholestasis
39. Extracellular matrix deposition, lysyl oxidase expression, and myofibroblastic differentiation during the initial stages of cholestatic fibrosis in the rat
40. Cellular sources of collagen and regulation of collagen production in liver
41. The role of the myofibroblast in wound healing and fibrocontractive diseases
42. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar
43. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors
44. CC14 cirrhosis in rats: Irreversible histological changes and differentiated functional impairment
45. The effects of experimental acute biliary obstruction and release on the rat liver. A histochemical study
46. Hepatic recovery after biliary decompression of experimental obstructive jaundice
47. Reversibility of hepatic fibrosis in experimentally induced cholestasis in rat
48. Reversibility of secondary biliary fibrosis by biliodigestive anastomosis in the rat
49. Reversibility of cholestatic changes following experimental common bile duct obstruction: Fact or fantasy?
50. Deletion of hyperplastic biliary epithelial cells by apoptosis following removal of the proliferative stimulus
51. Apoptosis during development of experimentally induced cholestasis in rat and after biliary decompression
52. Proteinases and tissue remodeling
53. Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis
54. The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-β1
55. Latent transforming growth factor-β1 and its binding protein are components Of extracellular matrix microfibrills
56. Rapamycin inhibits hepatic stellate cell proliferatin in vitro and limits fibrogenesis in an in vivo model of liver fibrosis
57. A soluble transforming growth factor beta receptor expressed in muscle prevents liver fibrogenesis and dysfunction in rats
58. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: A potential new therapy for hepatic fibrosis
59. The Ras antagonist, farnesylthiosalicylic acid (FTS), inhibits experimentally-induced liver cirrhosis in rats
60. Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery
61. An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis
62. Hepatocyte growth factor gene therapy of liver cirrhosis in rats
63. The decrease in total collagen fibers in the liver by hepatocyte growth factor after formation of cirrhosis induced by thioacetamide
64. The hepatic repair complex: Histologic features suggesting partial reversibility of cirrhosis
65. Idiopathic portal hypertension: Histologic evidence that some cases may be regressed cirrhosis with portal vein thrombosis
66. Most non-cirrhotic livers with hepatocellular carcinoma (HCC) have evidence of fibrosis or regressed cirrhosis: Implications for the pathogenesis of HCC
67. Non-invasive and early diagnosis of liver cirrhosis
68. TGF-beta in liver fibrosis: An inducible transgenic mouse model to study liver fibrogenesis
69. Telomerase is strongly activated in hepatocellular carcinoma but not in chronic hepatitis and cirrhosis